Lineage Cell Therapeutics, Inc. (LCTX) stock intrinsic value fair value estimate & owner earnings analysis

Lineage Cell Therapeutics develops cell therapies grown from stem cells. It has no approved product. Its income comes from partners: Roche and Genentech, which fund and run the lead program OpRegen (retinal pigment cells for geographic atrophy, an advanced form of dry age-related macular degeneration), and William Demant Invest, which funds early work on ReSonance for hearing loss. Its own spending goes mainly to OPC1 for spinal cord injury, now in the DOSED device study, and to overhead. The business has consumed cash every year. Measured after stock compensation and equipment spending, and with timing swings in receivables, payables and deferred revenue stripped out, it used about $20 million a year in 2023-2025 (roughly 9 to 13 cents a share), and the first half of 2026 ran at a somewhat faster pace. Years before 2019 describe a different, larger group of subsidiaries and were not used. The 2022 cash surge from Roche's $50 million upfront payment is spread over the years it was earned rather than counted when it arrived. There is no debt; at 30 June 2026 Lineage held $50.8 million of cash and securities, plus about $30 million collectable if warrants struck at $0.91 are exercised. The 10-K states cash is sufficient for at least twelve months but not to bring any product to approval, so further share issuance is expected. OpRegen is the only asset with contracted economics: up to $615 million of remaining Roche milestones and tiered double-digit royalties. These are gross figures. Roughly 21.5% of milestones go to Hadasit and a further share to the Israel Innovation Authority (from the December 2025 $5 million milestone, $2.3 million was owed onward), and up to half of royalties, capped at 5% of sales, go to Hadasit. Lineage keeps a bit over half of milestones and a majority of royalties. Roche is still optimising surgical delivery in the 60-patient Phase 2a GAlette study, so no registrational study has begun. Bear case ($0.01): Roche returns OpRegen after GAlette, as large partners often do with cell therapies at this stage. Lineage keeps spending about $20 million a year on OPC1 and overhead, the warrants go unexercised, and the cash is largely gone by 2028 before any program earns revenue. With no debt, the business owes nothing beyond its running costs, but shareholders are left with little more than residual cash after wind-down or heavy dilution. Base case ($0.13): OpRegen advances slowly; we give roughly a 45% chance of a Phase 3 start with its milestone and about a 20% chance of approval around 2032, with royalties of about $50 million a year to Lineage after onward payments at peak, running into the late 2030s on patents expiring around 2036 and manufacturing know-how. Probability-weighted, OpRegen is worth about $60 million today. Against that, Lineage keeps spending about $20 million a year through 2030 and a leaner amount after. Business value plus $81 million of cash and warrant proceeds, less no debt, gives about $38 million across about 288 million shares. Bull case ($1.20): OpRegen is approved early next decade, with peak sales near $1.2 billion against an established geographic atrophy market (pegcetacoplan and avacincaptad pegol already sell). Milestones and royalties net to Lineage are worth about $370 million today, less the spending needed to get there, again with no debt. No growth beyond the signed Roche contract is credited. OPC1, ReSonance and other programs have no signed commercial terms, so no value is given to them; their cost is counted. Margin of safety price: we are not confident of the earnings level because there are no earnings, only a spending rate that has varied with program choices. The worst plausible outcome, OpRegen returned, leaves almost nothing; the balance sheet has no debt but cannot fund a product to market without new shares. The things we are most likely to be wrong about are OpRegen's chance of success, the size of the market Roche reaches, and how much more Lineage spends and issues before an outcome; any one of these moves value by tens of cents. An outcome is at least five to seven years away, and nothing is paid to owners while waiting. On today's facts no price can be shown to support a 20% annual return. If Roche starts a registrational study, the milestone cash arrives, the hand-back risk falls sharply and the chance of approval roughly doubles; at that point, from a price of $0.12 the success outcome implies about eight to ten times that price within seven years, enough to absorb the realistic chance of failure and still imply a 20% annual return. That is the margin of safety price, and it applies only once that study is underway. Compared with our previous estimate, the business news is mixed: the cash position and Roche program status are essentially unchanged, while spending in the first half of 2026 ran faster than in 2025. The previous figures were built on a different basis and are not directly comparable.